Aduro BioTech Inc (NASDAQ:ADRO)’s share price was down 4.5% during mid-day trading on Wednesday . The company traded as low as $15.20 and last traded at $15.25, with a volume of 869,285 shares changing hands. The stock had previously closed at $15.97.

A number of equities analysts recently issued reports on ADRO shares. Canaccord Genuity reiterated a “buy” rating and issued a $30.00 target price on shares of Aduro BioTech in a research report on Friday, August 5th. FBR & Co reiterated a “buy” rating and issued a $34.00 target price (up previously from $30.00) on shares of Aduro BioTech in a research report on Saturday, May 14th. Leerink Swann reiterated a “buy” rating and issued a $48.00 target price on shares of Aduro BioTech in a research report on Thursday, May 5th. Roth Capital reiterated a “buy” rating and issued a $22.00 target price on shares of Aduro BioTech in a research report on Monday, July 11th. Finally, Zacks Investment Research downgraded shares of Aduro BioTech from a “hold” rating to a “sell” rating in a report on Monday, July 18th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. Aduro BioTech currently has a consensus rating of “Hold” and an average price target of $22.00.

The company’s 50 day moving average price is $13.18 and its 200-day moving average price is $13.24. The stock’s market capitalization is $987.50 million.

Aduro BioTech (NASDAQ:ADRO) last issued its earnings results on Wednesday, August 3rd. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.18) by $0.21. The firm earned $39 million during the quarter, compared to the consensus estimate of $25.24 million. The firm’s quarterly revenue was up 306.3% compared to the same quarter last year. On average, equities research analysts predict that Aduro BioTech Inc will post ($1.17) EPS for the current fiscal year.

In other Aduro BioTech news, insider Thomas W. Dubensky sold 25,000 shares of Aduro BioTech stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $11.61, for a total transaction of $290,250.00. Following the completion of the transaction, the insider now directly owns 13,939 shares of the company’s stock, valued at $161,831.79. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

A hedge fund recently raised its stake in Aduro BioTech stock. Jennison Associates LLC increased its position in shares of Aduro BioTech Inc (NASDAQ:ADRO) by 9.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 855,338 shares of the company’s stock after buying an additional 74,073 shares during the period. Jennison Associates LLC owned 1.35% of Aduro BioTech worth $24,069,000 as of its most recent SEC filing.

Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.